Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia

Joseph A. Eustace, Josef Coresh, Chris Kutchey, Purita L. Te, Luis F. Gimenez, Paul J. Scheel, Mackenzie Walser

Research output: Contribution to journalArticle

Abstract

Background. Hypoalbuminemia is associated with substantial morbidity and mortality in dialysis patients. Methods. Subjects with a mean three-month prestudy serum albumin of 3.8 g/dL or less and who demonstrated ≥90% compliance during a two-week run-in period were randomized to 3.6 g of essential amino acids (EAAs) or placebo three times daily with meals for three months. Randomization was stratified by dialysis modality and by severity of the hypoalbuminemia. The primary study outcome was change in the average of three monthly serum albumin measurements between baseline and follow-up. Results. Fifty-two patients were randomized; 47 patients (29 hemodialysis and 18 peritoneal dialysis) met the predetermined primary analysis criteria. The mean compliance rates averaged 75, 70, and 50% at months 1, 2, and 3, respectively, and were similar for EAAs and placebo. Serum albumin in the hemodialysis patients, EAA versus placebo, improved [(mean ± SE) 0.22 ± 0.09 g/dL, P = 0.02]. Changes in peritoneal dialysis patients were not significant (0.01 ± 0.15 g/dL), but approached significance for the total study group (0.14 ± 0.08 g/dL, P = 0.08). Patients in the very low albumin strata (

Original languageEnglish (US)
Pages (from-to)2527-2538
Number of pages12
JournalKidney International
Volume57
Issue number6
DOIs
StatePublished - 2000

Fingerprint

Hypoalbuminemia
Essential Amino Acids
Dialysis
Serum Albumin
Placebos
Peritoneal Dialysis
Renal Dialysis
Random Allocation
Compliance
Meals
Albumins
Outcome Assessment (Health Care)
Morbidity
Mortality

Keywords

  • Aminogram
  • C reactive protein
  • Dietary supplement
  • Malnutrition

ASJC Scopus subject areas

  • Nephrology

Cite this

Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. / Eustace, Joseph A.; Coresh, Josef; Kutchey, Chris; Te, Purita L.; Gimenez, Luis F.; Scheel, Paul J.; Walser, Mackenzie.

In: Kidney International, Vol. 57, No. 6, 2000, p. 2527-2538.

Research output: Contribution to journalArticle

Eustace, Joseph A. ; Coresh, Josef ; Kutchey, Chris ; Te, Purita L. ; Gimenez, Luis F. ; Scheel, Paul J. ; Walser, Mackenzie. / Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. In: Kidney International. 2000 ; Vol. 57, No. 6. pp. 2527-2538.
@article{ddf4c25795104db5b1d1403c9514b7b2,
title = "Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia",
abstract = "Background. Hypoalbuminemia is associated with substantial morbidity and mortality in dialysis patients. Methods. Subjects with a mean three-month prestudy serum albumin of 3.8 g/dL or less and who demonstrated ≥90{\%} compliance during a two-week run-in period were randomized to 3.6 g of essential amino acids (EAAs) or placebo three times daily with meals for three months. Randomization was stratified by dialysis modality and by severity of the hypoalbuminemia. The primary study outcome was change in the average of three monthly serum albumin measurements between baseline and follow-up. Results. Fifty-two patients were randomized; 47 patients (29 hemodialysis and 18 peritoneal dialysis) met the predetermined primary analysis criteria. The mean compliance rates averaged 75, 70, and 50{\%} at months 1, 2, and 3, respectively, and were similar for EAAs and placebo. Serum albumin in the hemodialysis patients, EAA versus placebo, improved [(mean ± SE) 0.22 ± 0.09 g/dL, P = 0.02]. Changes in peritoneal dialysis patients were not significant (0.01 ± 0.15 g/dL), but approached significance for the total study group (0.14 ± 0.08 g/dL, P = 0.08). Patients in the very low albumin strata (",
keywords = "Aminogram, C reactive protein, Dietary supplement, Malnutrition",
author = "Eustace, {Joseph A.} and Josef Coresh and Chris Kutchey and Te, {Purita L.} and Gimenez, {Luis F.} and Scheel, {Paul J.} and Mackenzie Walser",
year = "2000",
doi = "10.1046/j.1523-1755.2000.00112.x",
language = "English (US)",
volume = "57",
pages = "2527--2538",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia

AU - Eustace, Joseph A.

AU - Coresh, Josef

AU - Kutchey, Chris

AU - Te, Purita L.

AU - Gimenez, Luis F.

AU - Scheel, Paul J.

AU - Walser, Mackenzie

PY - 2000

Y1 - 2000

N2 - Background. Hypoalbuminemia is associated with substantial morbidity and mortality in dialysis patients. Methods. Subjects with a mean three-month prestudy serum albumin of 3.8 g/dL or less and who demonstrated ≥90% compliance during a two-week run-in period were randomized to 3.6 g of essential amino acids (EAAs) or placebo three times daily with meals for three months. Randomization was stratified by dialysis modality and by severity of the hypoalbuminemia. The primary study outcome was change in the average of three monthly serum albumin measurements between baseline and follow-up. Results. Fifty-two patients were randomized; 47 patients (29 hemodialysis and 18 peritoneal dialysis) met the predetermined primary analysis criteria. The mean compliance rates averaged 75, 70, and 50% at months 1, 2, and 3, respectively, and were similar for EAAs and placebo. Serum albumin in the hemodialysis patients, EAA versus placebo, improved [(mean ± SE) 0.22 ± 0.09 g/dL, P = 0.02]. Changes in peritoneal dialysis patients were not significant (0.01 ± 0.15 g/dL), but approached significance for the total study group (0.14 ± 0.08 g/dL, P = 0.08). Patients in the very low albumin strata (

AB - Background. Hypoalbuminemia is associated with substantial morbidity and mortality in dialysis patients. Methods. Subjects with a mean three-month prestudy serum albumin of 3.8 g/dL or less and who demonstrated ≥90% compliance during a two-week run-in period were randomized to 3.6 g of essential amino acids (EAAs) or placebo three times daily with meals for three months. Randomization was stratified by dialysis modality and by severity of the hypoalbuminemia. The primary study outcome was change in the average of three monthly serum albumin measurements between baseline and follow-up. Results. Fifty-two patients were randomized; 47 patients (29 hemodialysis and 18 peritoneal dialysis) met the predetermined primary analysis criteria. The mean compliance rates averaged 75, 70, and 50% at months 1, 2, and 3, respectively, and were similar for EAAs and placebo. Serum albumin in the hemodialysis patients, EAA versus placebo, improved [(mean ± SE) 0.22 ± 0.09 g/dL, P = 0.02]. Changes in peritoneal dialysis patients were not significant (0.01 ± 0.15 g/dL), but approached significance for the total study group (0.14 ± 0.08 g/dL, P = 0.08). Patients in the very low albumin strata (

KW - Aminogram

KW - C reactive protein

KW - Dietary supplement

KW - Malnutrition

UR - http://www.scopus.com/inward/record.url?scp=0034036505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034036505&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2000.00112.x

DO - 10.1046/j.1523-1755.2000.00112.x

M3 - Article

C2 - 10844622

AN - SCOPUS:0034036505

VL - 57

SP - 2527

EP - 2538

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -